Caliway Biopharmaceuticals secures US FDA IND clearance for CBL-0302, a global phase 3 clinical trial evaluating CBL-514 for non-surgical abdominal fat reduction.
Aesthetic Medicine | 28/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy